The urobiome, the microbial community within the urinary tract, is key to urological health and immune modulation. Recent advances in immunogenomics have revealed intricate interactions between the urobiome and host immune mechanisms, influencing the development and progression of urological cancers and infections. Immunogenomics is particularly useful in diagnosing emerging or rare infections where pathogen profiles are unclear and can provide insights into atypical immune responses. Multi-omics approaches, including genomics, proteomics, and metabolomics, enable a deeper understanding of these complex interactions at a single-cell level, shedding light on disease pathogenesis and treatment responses. Molecular diagnostics has thus become a vital tool for detecting urological conditions, providing precise identification of pathogens and cancer markers. By integrating these advanced methodologies, researchers can uncover novel biomarkers and therapeutic targets, paving the way for personalized treatment strategies. This research area offers significant potential for improving diagnostic accuracy and therapeutic outcomes in urological cancers and infections.
Urological cancers and infections present significant clinical challenges due to their complex etiology and varied treatment responses. Traditional diagnostic methods often lack the precision needed to accurately characterize these conditions, leading to suboptimal treatment outcomes. The need for a comprehensive understanding of uropathogens beyond the “usual suspects” cannot be overstated. Its role in modulating the immune response and its interactions with host genetics remain poorly understood, limiting our ability to leverage this knowledge for therapeutic benefit. Additionally, the rise of antibiotic resistance in urological infections calls for innovative diagnostic and treatment approaches. Recent advances in multi-omics technologies, such as genomics, proteomics, and metabolomics, offer unprecedented opportunities to dissect the urobiome-host interactions at a molecular-level. Molecular diagnostics have enhanced the detection and characterization of uropathogens and cancer markers, facilitating early diagnosis and personalized treatment strategies. Integrating these technologies can provide a comprehensive understanding of the urobiome’s impact on urological cancers and infections. To address this problem, this Research Topic aims to explore the potential of molecular diagnostics and multi-omics to identify novel biomarkers, unravel the mechanisms underlying disease progression, and develop innovative treatment approaches. By doing so, we can improve diagnostic accuracy and therapeutic outcomes for patients with urological conditions.
The scope of this Research Topic focuses on exploring the role of the urobiome and immunogenomics in urological cancers and infections through multi-omics and molecular diagnostics. We encourage submissions that delve into themes such as the interplay between the urobiome and host immune responses, the development of innovative molecular diagnostic tools and protocols, and the identification of novel biomarkers for early detection and targeted therapy. Contributions exploring antibiotic resistance in urological infections, single-cell analysis of urobiome-host interactions, and impact of urobiome modulation on treatment outcomes, epidemiological trends of urological cancers and urological infections are also welcome.
We invite original research articles, reviews, mini-reviews, methods and protocols, detailed interesting case-reports, commentary, and perspective pieces that provide novel insights or comprehensive overviews in this field. Submissions should advance our understanding of the urobiome’s role in urological health and disease, offering potential pathways for improving patient care.
Keywords:
Urobiome, Immunogenomics, Urological Cancers, Urological Infections, Molecular Diagnostics
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The urobiome, the microbial community within the urinary tract, is key to urological health and immune modulation. Recent advances in immunogenomics have revealed intricate interactions between the urobiome and host immune mechanisms, influencing the development and progression of urological cancers and infections. Immunogenomics is particularly useful in diagnosing emerging or rare infections where pathogen profiles are unclear and can provide insights into atypical immune responses. Multi-omics approaches, including genomics, proteomics, and metabolomics, enable a deeper understanding of these complex interactions at a single-cell level, shedding light on disease pathogenesis and treatment responses. Molecular diagnostics has thus become a vital tool for detecting urological conditions, providing precise identification of pathogens and cancer markers. By integrating these advanced methodologies, researchers can uncover novel biomarkers and therapeutic targets, paving the way for personalized treatment strategies. This research area offers significant potential for improving diagnostic accuracy and therapeutic outcomes in urological cancers and infections.
Urological cancers and infections present significant clinical challenges due to their complex etiology and varied treatment responses. Traditional diagnostic methods often lack the precision needed to accurately characterize these conditions, leading to suboptimal treatment outcomes. The need for a comprehensive understanding of uropathogens beyond the “usual suspects” cannot be overstated. Its role in modulating the immune response and its interactions with host genetics remain poorly understood, limiting our ability to leverage this knowledge for therapeutic benefit. Additionally, the rise of antibiotic resistance in urological infections calls for innovative diagnostic and treatment approaches. Recent advances in multi-omics technologies, such as genomics, proteomics, and metabolomics, offer unprecedented opportunities to dissect the urobiome-host interactions at a molecular-level. Molecular diagnostics have enhanced the detection and characterization of uropathogens and cancer markers, facilitating early diagnosis and personalized treatment strategies. Integrating these technologies can provide a comprehensive understanding of the urobiome’s impact on urological cancers and infections. To address this problem, this Research Topic aims to explore the potential of molecular diagnostics and multi-omics to identify novel biomarkers, unravel the mechanisms underlying disease progression, and develop innovative treatment approaches. By doing so, we can improve diagnostic accuracy and therapeutic outcomes for patients with urological conditions.
The scope of this Research Topic focuses on exploring the role of the urobiome and immunogenomics in urological cancers and infections through multi-omics and molecular diagnostics. We encourage submissions that delve into themes such as the interplay between the urobiome and host immune responses, the development of innovative molecular diagnostic tools and protocols, and the identification of novel biomarkers for early detection and targeted therapy. Contributions exploring antibiotic resistance in urological infections, single-cell analysis of urobiome-host interactions, and impact of urobiome modulation on treatment outcomes, epidemiological trends of urological cancers and urological infections are also welcome.
We invite original research articles, reviews, mini-reviews, methods and protocols, detailed interesting case-reports, commentary, and perspective pieces that provide novel insights or comprehensive overviews in this field. Submissions should advance our understanding of the urobiome’s role in urological health and disease, offering potential pathways for improving patient care.
Keywords:
Urobiome, Immunogenomics, Urological Cancers, Urological Infections, Molecular Diagnostics
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.